Nfe2l2 Rat shRNA Plasmid (Locus ID 83619)

SKU
TL711582
Nfe2l2 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
  $1,013.00
In Stock*
Specifications
Specifications
Product Data
Locus ID 83619
Vector pGFP-C-shLenti
E. coli Selection Chloramphenicol (34 ug/ml)
Mammalian Cell Selection Puromycin
Format Lentiviral plasmids
Components Nfe2l2 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 83619). 5µg purified plasmid DNA per construct
29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq NM_031789, NM_031789.1, NM_031789.2, BC061724
UniProt ID O54968
Summary a basic leucine zipper transcription factor; involved in activating expression of genes with an antioxidant response element (ARE) RGD, Feb 2006
shRNA Design These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Storage Store at -20°C
Shipping Ambient
Reviews
 
 
 
 
 

Be the first to review this product

Please note:
Only reviews with images are eligible for a $20/20€ Amazon gift card.
Reviews without images are eligible for a $10/10€ Amazon gift card.
For more details about the terms and conditions, please visit the promotion page.

Review image
Documents
Resources

file-alt Citations

FGF9 alleviates diabetic cardiomyopathy by activating Nrf2 via SQSTM1/p62-Keap1 in mice
An, Chen, Li et al
Commun Biol (2025) 8 (1), 1681 DOI: 10.1038/s42003-025-09077-6
Cited by 5
AI Summary: OriGene’s Nrf2-targeting shRNA (TL711582) was used in this study to transiently knock down Nrf2 expression in neonatal rat cardiomyocytes, enabling the authors to investigate the role of Nrf2 in FGF9-mediated cardioprotection against diabetic cardiomyopathy.
Snippet: l rat cardiomyocytes (NRCMs) NRCMs were isolated from the ventricles of Sprague-Dawley rats at postnatal day 2, as previously described76,77. Transient transfection of Nrf2-targeting shRNA (TL711582, ORIGENE) or control shRNA was performed in NRCMs using Lipofectamine RNAiMAX (Invitrogen) following the manufacturer’s protocol. NRCMs were subsequently treated with mannitol (33 mM: 5.5 mM gluc
FigureFigureFigure
Showing 1-1 of 1 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Related Products